Tags

Type your tag names separated by a space and hit enter

I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.
PLoS One. 2011; 6(11):e27622.Plos

Abstract

BACKGROUND

In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza.

METHODS

Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination.

RESULTS

We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ≥60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B.

CONCLUSIONS

Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.

Authors+Show Affiliations

EpiConcept, Paris, France. e.kissling@epiconcept.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

22110695

Citation

Kissling, Esther, et al. "I-MOVE Multi-centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe." PloS One, vol. 6, no. 11, 2011, pp. e27622.
Kissling E, Valenciano M, Cohen JM, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS ONE. 2011;6(11):e27622.
Kissling, E., Valenciano, M., Cohen, J. M., Oroszi, B., Barret, A. S., Rizzo, C., Stefanoff, P., Nunes, B., Pitigoi, D., Larrauri, A., Daviaud, I., Horvath, J. K., O'Donnell, J., Seyler, T., Paradowska-Stankiewicz, I. A., Pechirra, P., Ivanciuc, A. E., Jiménez-Jorge, S., Savulescu, C., ... Moren, A. (2011). I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PloS One, 6(11), e27622. https://doi.org/10.1371/journal.pone.0027622
Kissling E, et al. I-MOVE Multi-centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLoS ONE. 2011;6(11):e27622. PubMed PMID: 22110695.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. AU - Kissling,Esther, AU - Valenciano,Marta, AU - Cohen,Jean Marie, AU - Oroszi,Beatrix, AU - Barret,Anne-Sophie, AU - Rizzo,Caterina, AU - Stefanoff,Pawel, AU - Nunes,Baltazar, AU - Pitigoi,Daniela, AU - Larrauri,Amparo, AU - Daviaud,Isabelle, AU - Horvath,Judit Krisztina, AU - O'Donnell,Joan, AU - Seyler,Thomas, AU - Paradowska-Stankiewicz,Iwona Anna, AU - Pechirra,Pedro, AU - Ivanciuc,Alina Elena, AU - Jiménez-Jorge,Silvia, AU - Savulescu,Camelia, AU - Ciancio,Bruno Christian, AU - Moren,Alain, Y1 - 2011/11/15/ PY - 2011/09/09/received PY - 2011/10/20/accepted PY - 2011/11/24/entrez PY - 2011/11/24/pubmed PY - 2012/3/27/medline SP - e27622 EP - e27622 JF - PloS one JO - PLoS ONE VL - 6 IS - 11 N2 - BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. METHODS: Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination. RESULTS: We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ≥60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B. CONCLUSIONS: Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/22110695/I_MOVE_multi_centre_case_control_study_2010_11:_overall_and_stratified_estimates_of_influenza_vaccine_effectiveness_in_Europe_ L2 - http://dx.plos.org/10.1371/journal.pone.0027622 DB - PRIME DP - Unbound Medicine ER -